Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Streptococcus pneumoniae serotype 5 capsular polysaccharide (CPS) is a surface polysaccharide that forms a protective capsule essential for bacterial virulence, enabling nasopharyngeal colonization, evasion of host phagocytosis, adhesion, biofilm formation, and resistance to complement-mediated killing. It is synthesized via the Wzy-dependent pathway, with repeat units assembled on lipid carriers, translocated across the membrane, polymerized, and covalently linked via a direct 1,6-glycosidic bond from the reducing-end glucose to GlcNAc in peptidoglycan. This CPS is a key vaccine antigen in formulations like PCV13, targeting serotype-specific immunity to prevent pneumococcal diseases such as pneumonia and sepsis.
Antibody induction against CPS for opsonophagocytosis and bacterial clearance
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae serotype 5 capsular polysaccharide (null).